C1 Inhibitor (Human) Market Report

China C1 Inhibitor (Human) Industry Market Research Report 2023-2029

  • POSTDATE：Sep 01, 2023
  • PAGES：231
  • REPORT CODE：GMM1768915
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the C1 Inhibitor (Human) industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Sanquin

    • Viropharma Biologics Inc

    • BioCryst Pharmaceuticals

    • Pharming Group

    • Lev Pharmaceuticals

    • iBio Inc

    • CSL Behring

    • Salix Pharmaceuticals

    • Ionis Pharmaceuticals Inc

    By Type:

    • Subcutaneous

    • Intravenous

    By Application:

    • Pharmacies

    • Hospitals

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China C1 Inhibitor (Human) Market Overview 2018-2029

    • 1.1 China C1 Inhibitor (Human) Industry Development Overview

    • 1.2 China C1 Inhibitor (Human) Industry Development History

    • 1.3 China C1 Inhibitor (Human) Industry Market Size (2018-2029)

    • 1.4 China C1 Inhibitor (Human) Market Analysis by Type from Production Side

      • 1.4.1 China C1 Inhibitor (Human) Production Volume, Production Value and Growth Rate of Subcutaneous (2018-2029)

      • 1.4.2 China C1 Inhibitor (Human) Production Volume, Production Value and Growth Rate of Intravenous (2018-2029)

    • 1.5 China C1 Inhibitor (Human) Market Analysis by Application from Consumption End

      • 1.5.1 China C1 Inhibitor (Human) Sales Volume, Sales Value and Growth Rate of Pharmacies (2018-2029)

      • 1.5.2 China C1 Inhibitor (Human) Sales Volume, Sales Value and Growth Rate of Hospitals (2018-2029)

    • 1.6 China C1 Inhibitor (Human) Market Analysis by Region

      • 1.6.1 North China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    Chapter 2 China C1 Inhibitor (Human) Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on C1 Inhibitor (Human) Market Status and Competition at home and abroad in 2023

      • 2.2.2 China C1 Inhibitor (Human) Market Status and Competition Analysis in 2023

      • 2.2.3 China C1 Inhibitor (Human) Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China C1 Inhibitor (Human) Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on C1 Inhibitor (Human) Industry Development

    Chapter 3 C1 Inhibitor (Human)Industry Chain Analysis

    • 3.1 C1 Inhibitor (Human) Industry Chain

    • 3.2 C1 Inhibitor (Human) Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the C1 Inhibitor (Human) Market

    • 3.3 C1 Inhibitor (Human) Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the C1 Inhibitor (Human) Market

    Chapter 4 China C1 Inhibitor (Human) Market, by Type

    • 4.1 China C1 Inhibitor (Human) Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China C1 Inhibitor (Human) Total Production Volume and Growth Rate from Production Side

    • 4.5 China C1 Inhibitor (Human) Production Volume and Growth Rate, by Type

      • 4.5.1 China C1 Inhibitor (Human) Production Volume and Growth Rate of Subcutaneous

      • 4.5.2 China C1 Inhibitor (Human) Production Volume and Growth Rate of Intravenous

    Chapter 5 China C1 Inhibitor (Human) Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China C1 Inhibitor (Human) Total Market Size and Growth Rate from Consumption End

    • 5.5 China C1 Inhibitor (Human) Market Size and Growth Rate, by Application

      • 5.5.1 China C1 Inhibitor (Human) Market Size and Growth Rate of Pharmacies

      • 5.5.2 China C1 Inhibitor (Human) Market Size and Growth Rate of Hospitals

    Chapter 6 China C1 Inhibitor (Human) Market, by Region

    • 6.1 China C1 Inhibitor (Human) Production Volume and Production Value, by Region

    • 6.2 China C1 Inhibitor (Human) Sales Volume and Sales Value, by Region

    Chapter 7 North China C1 Inhibitor (Human) Market Analysis

    • 7.1 North China C1 Inhibitor (Human) Market, by Type

    • 7.2 North China C1 Inhibitor (Human) Market, by Application

    Chapter 8 Central China C1 Inhibitor (Human) Market Analysis

    • 8.1 Central China C1 Inhibitor (Human) Market, by Type

    • 8.2 Central China C1 Inhibitor (Human) Market, by Application

    Chapter 9 South China C1 Inhibitor (Human) Market Analysis

    • 9.1 South China C1 Inhibitor (Human) Market, by Type

    • 9.2 South China C1 Inhibitor (Human) Market, by Application

    Chapter 10 East China C1 Inhibitor (Human) Market Analysis

    • 10.1 East China C1 Inhibitor (Human) Market, by Type

    • 10.2 East China C1 Inhibitor (Human) Market, by Application

    Chapter 11 Northeast China C1 Inhibitor (Human) Market Analysis

    • 11.1 Northeast China C1 Inhibitor (Human) Market, by Type

    • 11.2 Northeast China C1 Inhibitor (Human) Market, by Application

    Chapter 12 Southwest China C1 Inhibitor (Human) Market Analysis

    • 12.1 Southwest China C1 Inhibitor (Human) Market, by Type

    • 12.2 Southwest China C1 Inhibitor (Human) Market, by Application

    Chapter 13 Northwest China C1 Inhibitor (Human) Market Analysis

    • 13.1 Northwest China C1 Inhibitor (Human) Market, by Type

    • 13.2 Northwest China C1 Inhibitor (Human) Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Sanquin

        • 14.1.1 Sanquin Company Profile

        • 14.1.2 Sanquin C1 Inhibitor (Human) Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Viropharma Biologics Inc

        • 14.2.1 Viropharma Biologics Inc Company Profile

        • 14.2.2 Viropharma Biologics Inc C1 Inhibitor (Human) Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 BioCryst Pharmaceuticals

        • 14.3.1 BioCryst Pharmaceuticals Company Profile

        • 14.3.2 BioCryst Pharmaceuticals C1 Inhibitor (Human) Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Pharming Group

        • 14.4.1 Pharming Group Company Profile

        • 14.4.2 Pharming Group C1 Inhibitor (Human) Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Lev Pharmaceuticals

        • 14.5.1 Lev Pharmaceuticals Company Profile

        • 14.5.2 Lev Pharmaceuticals C1 Inhibitor (Human) Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 iBio Inc

        • 14.6.1 iBio Inc Company Profile

        • 14.6.2 iBio Inc C1 Inhibitor (Human) Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 CSL Behring

        • 14.7.1 CSL Behring Company Profile

        • 14.7.2 CSL Behring C1 Inhibitor (Human) Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Salix Pharmaceuticals

        • 14.8.1 Salix Pharmaceuticals Company Profile

        • 14.8.2 Salix Pharmaceuticals C1 Inhibitor (Human) Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Ionis Pharmaceuticals Inc

        • 14.9.1 Ionis Pharmaceuticals Inc Company Profile

        • 14.9.2 Ionis Pharmaceuticals Inc C1 Inhibitor (Human) Market Performance

        • 14.9.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 C1 Inhibitor (Human) Industry Research Conclusions

    • 15.2 C1 Inhibitor (Human) Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China C1 Inhibitor (Human) Industry Market Size (2018-2029)

    • Figure China C1 Inhibitor (Human) Production Volume, Production Value and Growth Rate of Subcutaneous (2018-2029)

    • Figure China C1 Inhibitor (Human) Production Volume, Production Value and Growth Rate of Intravenous (2018-2029)

    • Figure China C1 Inhibitor (Human) Sales Volume, Sales Value and Growth Rate of Pharmacies (2018-2029)

    • Figure China C1 Inhibitor (Human) Sales Volume, Sales Value and Growth Rate of Hospitals (2018-2029)

    • Figure North China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    • Figure Central China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    • Figure South China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    • Figure East China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    • Figure Northeast China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    • Figure Southwest China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    • Figure Northwest China C1 Inhibitor (Human) Market Size and Growth Rate from 2018-2029

    • Figure C1 Inhibitor (Human) Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China C1 Inhibitor (Human) Market Share by Type in 2018

    • Figure China C1 Inhibitor (Human) Market Share by Type in 2023

    • Figure China C1 Inhibitor (Human) Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China C1 Inhibitor (Human) Production Volume and Growth Rate of Subcutaneous (2018-2023)

    • Figure China C1 Inhibitor (Human) Production Volume and Growth Rate of Intravenous (2018-2023)

    • Figure China C1 Inhibitor (Human) Market Share by Application in 2018

    • Figure China C1 Inhibitor (Human) Market Share by Application in 2023

    • Figure China C1 Inhibitor (Human) Total Market Size and Growth Rate from Consumption End

    • Figure China C1 Inhibitor (Human) Market Size and Growth Rate of Pharmacies (2018-2023)

    • Figure China C1 Inhibitor (Human) Market Size and Growth Rate of Hospitals (2018-2023)

    • Table China C1 Inhibitor (Human) Production Volume by Region (2018-2023)

    • Table China C1 Inhibitor (Human) Production Volume Share by Region (2018-2023)

    • Figure China C1 Inhibitor (Human) Production Volume Share by Region (2018-2023)

    • Table China C1 Inhibitor (Human) Production Value by Region (2018-2023)

    • Table China C1 Inhibitor (Human) Production Value Share by Region (2018-2023)

    • Figure China C1 Inhibitor (Human) Production Value Share by Region (2018-2023)

    • Table China C1 Inhibitor (Human) Sales Volume by Region (2018-2023)

    • Table China C1 Inhibitor (Human) Sales Volume Share by Region (2018-2023)

    • Figure China C1 Inhibitor (Human) Sales Volume Share by Region (2018-2023)

    • Table China C1 Inhibitor (Human) Sales Value by Region (2018-2023)

    • Table China C1 Inhibitor (Human) Sales Value Share by Region (2018-2023)

    • Figure China C1 Inhibitor (Human) Sales Value Share by Region (2018-2023)

    • Table North China C1 Inhibitor (Human) Production Volume by Type (2018-2023)

    • Table North China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Figure North China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Table North China C1 Inhibitor (Human) Sales Volume by Application (2018-2023)

    • Table North China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Figure North China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Table Central China C1 Inhibitor (Human) Production Volume by Type (2018-2023)

    • Table Central China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Figure Central China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Table Central China C1 Inhibitor (Human) Sales Volume by Application (2018-2023)

    • Table Central China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Figure Central China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Table South China C1 Inhibitor (Human) Production Volume by Type (2018-2023)

    • Table South China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Figure South China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Table South China C1 Inhibitor (Human) Sales Volume by Application (2018-2023)

    • Table South China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Figure South China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Table East China C1 Inhibitor (Human) Production Volume by Type (2018-2023)

    • Table East China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Figure East China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Table East China C1 Inhibitor (Human) Sales Volume by Application (2018-2023)

    • Table East China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Figure East China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Table Northeast China C1 Inhibitor (Human) Production Volume by Type (2018-2023)

    • Table Northeast China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Figure Northeast China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Table Northeast China C1 Inhibitor (Human) Sales Volume by Application (2018-2023)

    • Table Northeast China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Figure Northeast China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Table Southwest China C1 Inhibitor (Human) Production Volume by Type (2018-2023)

    • Table Southwest China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Figure Southwest China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Table Southwest China C1 Inhibitor (Human) Sales Volume by Application (2018-2023)

    • Table Southwest China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Figure Southwest China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Table Northwest China C1 Inhibitor (Human) Production Volume by Type (2018-2023)

    • Table Northwest China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Figure Northwest China C1 Inhibitor (Human) Production Volume Share by Type (2018-2023)

    • Table Northwest China C1 Inhibitor (Human) Sales Volume by Application (2018-2023)

    • Table Northwest China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Figure Northwest China C1 Inhibitor (Human) Sales Volume Share by Application (2018-2023)

    • Table Sanquin Company Profile

    • Table Sanquin C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table Viropharma Biologics Inc Company Profile

    • Table Viropharma Biologics Inc C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table BioCryst Pharmaceuticals Company Profile

    • Table BioCryst Pharmaceuticals C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table Pharming Group Company Profile

    • Table Pharming Group C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table Lev Pharmaceuticals Company Profile

    • Table Lev Pharmaceuticals C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table iBio Inc Company Profile

    • Table iBio Inc C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table CSL Behring Company Profile

    • Table CSL Behring C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table Salix Pharmaceuticals Company Profile

    • Table Salix Pharmaceuticals C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)

    • Table Ionis Pharmaceuticals Inc Company Profile

    • Table Ionis Pharmaceuticals Inc C1 Inhibitor (Human) Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US